Metka Lenassi

Dr. Metka Lenassi

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2018 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
CTClotilde Théry
Clotilde Théry
KWKenneth Witwer
Kenneth Witwer
EAElena Aikawa
Elena Aikawa
MAMaria Jose Alcaraz
Maria Jose Alcaraz
JAJohnathon Anderson
Johnathon Anderson
Ewa Zuba-SurmaEwa Zuba-Surma
Ewa Zuba-Surma
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell‐released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV‐associated functional activities. Finally, a checklist is provided with summaries of key points.

7 February 2024 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
Joshua WelshJoshua Welsh
Joshua Welsh
DGDeborah Goberdhan
Deborah Goberdhan
LOLorraine O'Driscoll
Lorraine O'Driscoll
EBEdit Buzas
Edit Buzas
CBCherie Blenkiron
Cherie Blenkiron
KWKenneth Witwer
Kenneth Witwer
Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year‐on‐year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non‐vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its ‘Minimal Information for Studies of Extracellular Vesicles’, which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly.

8 December 2009 in Traffic
Verified
Journal Article
Open access
PDF file
MLMetka Lenassi
Metka Lenassi
GCGerard Cagney
Gerard Cagney
MLMaofu Liao
Maofu Liao
TVTomaž Vaupotič
Tomaž Vaupotič
KBKoen Bartholomeeusen
Koen Bartholomeeusen
Boris PeterlinBoris Peterlin
Boris Peterlin
The HIV accessory protein negative factor (Nef) is one of the earliest and most abundantly expressed viral proteins. It is also found in the serum of infected individuals (Caby MP, Lankar D, Vincendeau‐Scherrer C, Raposo G, Bonnerot C. Exosomal‐like vesicles are present in human blood plasma. Int Immunol 2005;17:879–887). Extracellular Nef protein has deleterious effects on CD4+ T cells (James CO, Huang MB, Khan M, Garcia‐Barrio M, Powell MD, Bond VC. Extracellular Nef protein targets CD4+ T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 2004;78:3099–3109), the primary targets of HIV, and can suppress immunoglobulin class switching in bystander B cells (Qiao X, He B, Chiu A, Knowles DM, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40‐dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006;7:302–310). Nevertheless, the mode of exit of Nef from infected cells remains a conundrum. We found that Nef stimulates its own export via the release of exosomes from all cells examined. Depending on its intracellular location, these Nef exosomes form at the plasma membrane, late endosomes or both compartments in Jurkat, SupT1 and primary T cells, respectively. Nef release through exosomes is conserved also during HIV‐1 infection of peripheral blood lymphocytes (PBLs). Released Nef exosomes cause activation‐induced cell death of resting PBLs in vitro. Thus, HIV‐infected cells export Nef in bioactive vesicles, which facilitate the depletion of CD4+ T cells that is a hallmark of acquired immunodeficiency syndrome (AIDS).

1 June 2018 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
PDPia Pužar Dominkuš
Pia Pužar Dominkuš
MSMatjaz Stenovec
Matjaz Stenovec
SSSimona Sitar
Simona Sitar
ELEva Lasič
Eva Lasič
Robert ZorecRobert Zorec
Robert Zorec
MLMetka Lenassi
Metka Lenassi

20 August 2015 in Analytical Chemistry
Verified
Journal Article
Closed access
SSSimona Sitar
Simona Sitar
AKAnja Kejžar
Anja Kejžar
DPDavid Pahovnik
David Pahovnik
KKKsenija Kogej
Ksenija Kogej
MTMagda Tušek-Žnidarič
Magda Tušek-Žnidarič
EŽEma Žagar
Ema Žagar

8 December 2023 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
Fabrice LucienFabrice Lucien
Fabrice Lucien
DGDakota Gustafson
Dakota Gustafson
MLMetka Lenassi
Metka Lenassi
BLBo Li
Bo Li
JTJacob J. Teske
Jacob J. Teske
RNRienk Nieuwland
Rienk Nieuwland
Blood is the most commonly used body fluid for extracellular vesicle (EV) research. The composition of a blood sample and its derivatives (i.e., plasma and serum) are not only donor‐dependent but also influenced by collection and preparation protocols. Since there are hundreds of pre‐analytical protocols and over forty variables, the development of standard operating procedures for EV research is very challenging. To improve the reproducibility of blood EV research, the International Society for Extracellular Vesicles (ISEV) Blood EV Task Force proposes standardized reporting of (i) the applied blood collection and preparation protocol and (ii) the quality of the prepared plasma and serum samples. Gathering detailed information will provide insight into the performance of the protocols and more effectively identify potential confounders in the prepared plasma and serum samples. To collect this information, the ISEV Blood EV Task Force created the Minimal Information for Blood EV research (MIBlood‐EV), a tool to record and report information about pre‐analytical protocols used for plasma and serum preparation as well as assays used to assess the quality of these preparations. This tool does not require modifications of established local pre‐analytical protocols and can be easily implemented to enhance existing databases thereby enabling evidence‐based optimization of pre‐analytical protocols through meta‐analysis. Taken together, insight into the quality of prepared plasma and serum samples will (i) improve the quality of biobanks for EV research, (ii) guide the exchange of plasma and serum samples between biobanks and laboratories, (iii) facilitate inter‐laboratory comparative EV studies, and (iv) improve the peer review process.